女性腹主动脉瘤筛查的临床获益、危害与成本效果分析
本研究通过决策模型评估女性腹主动脉瘤筛查的获益、危害与成本效果。按英国男性现行方案筛查女性,30年增量成本效果比为每获得一个质量调整生命年£30 000(95%CI 12 000-87 000),每预防一例AAA相关死亡需邀请3900人,过度诊断率33%。按英国标准,类似男性的女性AAA筛查方案不太可能具有成本效果。
要点
- 按男性方案筛查女性,增量成本效果比为£30 000/QALY,过度诊断率33%。
- 改良女性方案增量成本效果比为£23 000/QALY,过度诊断率55%。
- 成本效果不确定性主要来自AAA患病率、主动脉直径分布及筛查对生活质量的影响。
核心结论
- 按英国标准,类似男性的女性AAA筛查方案不太可能具有成本效果。
- 需进一步研究女性主动脉直径分布及筛查相关生活质量下降以评估改良方案。
研究设计与样本
- 决策模型评估女性邀请AAA筛查与不邀请筛查人群的预设结局。
- 采用离散事件模拟模型涵盖筛查、监测与干预。
- 参数来源于系统文献综述、国家登记或行政数据库、大型AAA手术试验及英国NHS参考成本。
主要发现
- 按男性现行方案筛查女性,30年增量成本效果比为每QALY £30 000(95%CI 12 000-87 000)。
- 每预防一例AAA相关死亡需邀请3900人,过度诊断率33%。
- 改良女性方案增量成本效果比为每QALY £23 000(95%CI 9500-71 000)。
- 改良方案每预防一例AAA死亡需邀请1800人,过度诊断率55%。
- 成本效果比不确定性主要源于AAA患病率、女性不同年龄主动脉直径分布及筛查对生活质量的影响。
临床怎么用
- 按英国标准,不建议直接采用男性AAA筛查方案用于女性。
局限性
- 成本效果比存在较大不确定性,主要受AAA患病率、主动脉直径分布及生活质量影响驱动。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A third of deaths in the UK from ruptured abdominal aortic aneurysm (AAA) are in women. In men, national screening programmes reduce deaths from AAA and are cost-effective. The benefits, harms, and cost-effectiveness in offering a similar programme to women have not been formally assessed, and this was the aim of this study. METHODS: We developed a decision model to assess predefined outcomes of death caused by AAA, life years, quality-adjusted life years, costs, and the incremental cost-effectiveness ratio for a population of women invited to AAA screening versus a population who were not invited to screening. A discrete event simulation model was set up for AAA screening, surveillance, and intervention. Relevant women-specific parameters were obtained from sources including systematic literature reviews, national registry or administrative databases, major AAA surgery trials, and UK National Health Service reference costs. FINDINGS: AAA screening for women, as currently offered to UK men (at age 65 years, with an AAA diagnosis at an aortic diameter of ≥3·0 cm, and elective repair considered at ≥5·5cm) gave, over 30 years, an estimated incremental cost-effectiveness ratio of £30 000 (95% CI 12 000-87 000) per quality-adjusted life year gained, with 3900 invitations to screening required to prevent one AAA-related death and an overdiagnosis rate of 33%. A modified option for women (screening at age 70 years, diagnosis at 2·5 cm and repair at 5·0 cm) was estimated to have an incremental cost-effectiveness ratio of £23 000 (9500-71 000) per quality-adjusted life year and 1800 invitations to screening required to prevent one AAA-death, but an overdiagnosis rate of 55%. There was considerable uncertainty in the cost-effectiveness ratio, largely driven by uncertainty about AAA prevalence, the distribution of aortic sizes for women at different ages, and the effect of screening on quality of life. INTERPRETATION: By UK standards, an AAA screening programme for women, designed to be similar to that used to screen men, is unlikely to be cost-effective. Further research on the aortic diameter distribution in women and potential quality of life decrements associated with screening are needed to assess the full benefits and harms of modified options. FUNDING: UK National Institute for Health Research Health Technology Assessment programme.
引用
- Sweeting MJ, Masconi KL, Jones E, et al. Analysis of clinical benefit, harms, and cost-effectiveness of screening women for abdominal aortic aneurysm. Lancet. 2018. PMID: 30057105. doi:10.1016/S0140-6736(18)31222-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。